Company: ARMP
Filing Date: 2025-04-28
Form Type: DEF 14A
Source: 0001104659-25-040273
Chunk: 34

Company: Armata Pharmaceuticals, Inc.
Filing Date: 2025-04-28
Form: DEF 14A
Chunk 34
---
 the Merger. The Merger was treated as a reverse acquisition for accounting purposes and, as such, the historical financial statements of the accounting acquirer, C3J, have become Armata’s historical financial statements. Representatives of Ernst & Young are expected to be available at the meeting. They will have an opportunity to make a statement if they so desire and will be available to respond to appropriate questions. Neither our Bylaws nor other governing documents or law require shareholder ratification of the selection of Ernst & Young as the Company’s independent registered public accounting firm. However, the Audit Committee of the Board is submitting the selection of Ernst & Young to the shareholders for ratification as a matter of good corporate practice. If the shareholders fail to ratify the selection, the Audit Committee of the Board will reconsider whether or not to retain Ernst & Young. Even if the selection is ratified, the Audit Committee of the Board in its discretion may direct the appointment of different independent auditors at any time during the year if it determines that such a change would be in the best interests of the Company and its shareholders. In order for Proposal 3 to be approved, the number of shares cast “For” the proposal must exceed the number of shares cast “Against” the proposal. Abstentions and broker non-votes, if any, will have no effect on the outcome of the vote. Principal Accountant Fees and Services The following table represents aggregate fees incurred for Ernst & Young services for the years ended December 31, 2024 and 2023:

| ​                            | ​ | ​ | Fiscal Year EndedDecember 31, 2024 |   |         |   | ​ | ​ | Fiscal Year EndedDecember 31, 2023 |   |         |   | ​ |
|:-----------------------------|:--|:--|:-----------------------------------|:--|--------:|:--|:--|:--|:-----------------------------------|:--|--------:|:--|:--|
| Armata Pharmaceuticals, Inc. | ​ | ​ | ​                                  | ​ |       ​ | ​ | ​ | ​ | ​                                  | ​ |       ​ | ​ | ​ |
| Audit Fees                   | ​ | ​ | ​                                  | $ | 590,000 | ​ | ​ | ​ | ​                                  | $ | 693,000 | ​ | ​ |
| Audit Related Fees           | ​ | ​ | ​                                  | ​ |       — | ​ | ​ | ​ | ​                                  | ​ |